A Phase 2 interventional study of Futibatinib in Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer and Myeloid or Lymphoid Neoplasms (MLN), sponsored by Taiho Oncology, Inc.. Terminated at 61 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-08.
Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,055 studies in Neoplasm Metastasis with a site in United States — 347 open to participants now, 543 under way, 58 of them phase 3. Neoplasm Metastasis · United States.
Among the 2,055 studies in Neoplasm Metastasis with a site in United States, this one is the 471st largest by enrollment of the 1,864 interventional ones that give a count, is one of 89 that started in 2020, is one of 566 in phase 2, and was the 1,387th registered.
4,048 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.
Browse Neoplasm Metastasis studies →347 of the 2,055 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
SystImmune Inc. · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
LTZ Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 691 Neoplasm Metastasis studies recruiting now, 538 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,055 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 977 · Phase 2 855 · Phase 3 186 · Phase 4 15
First in 1978; this study’s year is marked. 89 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 115 is above the median of 50 across 3,273 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 43 across the 1,864 interventional studies, 100 across the 139 observational. Of the 1,391 that completed or were terminated, 602 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
926 of 2,055 have an industry lead sponsor. The 10 most frequent:
This study is registered under Taiho Oncology, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Taiho Oncology, Inc. is the lead sponsor of 66 studies on the registry; 9 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 13 (52%) have results posted.
Otsuka Holdings Co., Ltd. has 6 studies filed under Neoplasm Metastasis — fewer than ten, so there is no comparison to draw.
203 of the studies in Neoplasm Metastasis with a site in United States that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03525873Phase 3M.D. Anderson Cancer CenterA Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy | 2026-12-31 |
| NCT03927885Phase 3M.D. Anderson Cancer CenterOpen Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer | 2026-12-31 |
| NCT06947928Phase 3TuHURA Biosciences, Inc.Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | 2027-03-31 |
| NCT06506955Phase 3Taiho Oncology, Inc.Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | 2027-04 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
Add all 203 to your calendar (.ics) → With an account.
Among the 2,055 studies in Neoplasm Metastasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of futibatinib in patients with FGFR aberrations in 3 distinct cohorts. Patients will be enrolled into one of 3 cohorts: patients with advanced, metastatic or locally-advanced solid tumors harboring FGFR1-4 rearrangements (excluding primary brain tumors and intrahepatic cholangiocarcinoma [iCCA]); patients with gastric or gastro-esophageal junction (GEJ) cancer harboring FGFR2 amplification; and patients with myeloid or lymphoid neoplasms with FGFR1 rearrangements.
Study TAS-120-202 is an open-label, multinational, 3-arm Phase 2 study evaluating the efficacy, safety, tolerability, PK, and pharmacodynamics of futibatinib in patients with FGFR aberrations. Eligible patients will be assigned to 1 of 3 treatment cohorts based on diagnosis and FGFR gene aberration status.
Patients will receive futibatinib at an oral dose of 20 mg once a day on a continuous 28-day cycle.
The study will enroll approximately:
Treatment in all cohorts will continue until disease progression, unacceptable toxicity, or any other of the criteria for treatment discontinuation is met. For patients who discontinue treatment for reasons other than disease progression, tumor assessments should be continued until radiologic disease progression is documented or until initiation of subsequent new anticancer therapy (whichever occurs first).
Patients will be followed for survival every 12 weeks (±2 weeks) until survival events (deaths) have been reported for 75% of enrolled patients or the study is terminated early by the Sponsor.
Additional cohorts may be added in the future in case of new emerging efficacy data.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Known FGFR aberration status and tumor type that meet all of the criteria for 1 of the following cohorts:
a. Cohort A
i. -confirmed, locally-advanced, advanced, or solid tumors harboring a FGFR1-4
ii. per (RECIST) Version 1.1
iii. Had disease progression/recurrence after standard treatment for their cancer
b. Cohort B
i. Histologically-confirmed, locally-advanced, advanced, or metastatic gastric or gastroesophageal junction cancer harboring a FGFR2 amplification.
ii. Measurable disease per RECIST 1.1
iii. Received at least 2 prior systemic regimens for advanced/metastatic disease
iv. Experienced disease progression/recurrence during or after the most recent prior systemic treatment for advanced/metastatic gastric cancer or GEJ cancer
c. Cohort C
i. Confirmed myeloid or lymphoid neoplasms as defined by WHO criteria with a FGFR1 rearrangement
ii. Not a candidate for hematological stem cell transplant () or after HSCT and donor lymphocyte infusion, and progressed and not a candidate for other therapies
Exclusion Criteria:
History and/or current evidence of any of the following disorders:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with advanced or metastatic solid tumors harboring FGFR1-4 rearrangements received futibatinib 20 mg, oral tablets, once a day on a continuous 28-day cycle up to a maximum of 841 days.
Drug: Futibatinib
Participants with advanced or metastatic solid gastric or GEJ cancer harboring FGFR2 amplification received futibatinib 20 mg, oral tablets, once a day on a continuous 28-day cycle up to a maximum of 297 days.
Drug: Futibatinib
Participants with myeloid or lymphoid neoplasm harboring FGFR1 rearrangement were to receive futibatinib 20 mg, oral tablets, once a day on a continuous 28-day cycle until disease progression, unacceptable toxicity or other treatment discontinuation criteria are met.
Drug: Futibatinib
Futibatinib tablets were dosed orally every day on a continuous 28-day cycle
Also known as: TAS-120
Objective Response Rate (ORR) Based on Independent Central Review (IRC) in Cohorts A and B
ORR was defined as the percentage of participants experiencing a best overall response of partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors, RECIST version 1.1), based on IRC of radiological images. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. ORR was calculated based on the best overall response recorded from the start of treatment until progressive disease or start of subsequent new anticancer treatment. Percentages were rounded off to the nearest single decimal place.
Time frame: At the end of every 2 cycles until disease progression (Up to 31 months)
Complete Response (CR) Rate in Cohort C
CR rate was defined as the percentage of participants who achieved a CR (per response criteria for myeloid or lymphoid neoplasm) based on investigator assessment of imaging, peripheral blood, and bone marrow. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm.
Time frame: At the end of every 2 cycles until disease progression (Up to 31 months)
ORR Based on Investigator Assessment in Cohorts A and B
ORR was defined as the percentage of participants experiencing a best overall response of PR or CR (per RECIST 1.1), based on investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. ORR was calculated based on the best overall response recorded from the start of treatment until progressive disease or start of subsequent new anticancer treatment. Percentages were rounded off to the nearest single decimal place.
Time frame: At the end of every 2 cycles until disease progression (Up to 31 months)
Duration of Response (DOR) Based on IRC in Cohorts A, B and C
DOR was defined as the time from the first documentation of response (CR or PR in based on IRC) to the first documentation of objective tumor progression or death due to any cause, whichever occurs first. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. DOR was estimated using the Kaplan-Meier method.
Time frame: At the end of every 2 cycles until disease progression (Up to 31 months)
DOR Based on Investigator Assessment in Cohorts A, B and C
DOR was defined as the time from the first documentation of response (CR or PR in based on Investigator Assessment) to the first documentation of objective tumor progression or death due to any cause, whichever occurs first. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. DOR was estimated using the Kaplan-Meier method.
Time frame: At the end of every 2 cycles until disease progression (Up to 31 months)
Progression- Free Survival (PFS) Based on IRC in Cohorts A, B and C
PFS was defined as the time from first dose of the study therapy to the date of death (any cause) or disease progression (based on IRC), whichever occurs first. The PFS was analyzed using a Kaplan-Meier method, with PFS time being censored on the date of the last disease assessment. The 95% CI for median PFS was provided using the Kaplan-Meier procedure.
Time frame: At the end of every 2 cycles until disease progression (Up to 31 months)
PFS Based on Investigator Review in Cohorts A, B and C
PFS was defined as the time from first dose of the study therapy to the date of death (any cause) or disease progression (based on Investigator Review), whichever occurs first. The PFS was analyzed using a Kaplan-Meier method, with PFS time being censored on the date of the last disease assessment. The 95% CI for median PFS was provided using the Kaplan-Meier procedure.
Time frame: At the end of every 2 cycles until disease progression (Up to 31 months)
Overall Survival (OS) in Cohorts A, B and C
OS was defined as the time from the date of first dose to the death date. Participants without a documented death date were censored on the last date they were known to be alive. The OS was presented using a Kaplan-Meier estimate. The 95% CI for median OS was provided using the Kaplan-Meier procedure.
Time frame: Up to 31 months
Disease Control Rate (DCR) Based on IRC in Cohort A and B
DCR was defined as the percentage of participants experiencing a best overall response of stable disease (SD), PR, or CR (per RECIST 1.1), based on IRC. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), referencing the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of target lesion diameters from the smallest on study (including baseline), with an absolute increase of ≥ 5 mm, or the appearance of new lesions. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. Percentages were rounded off to the nearest single decimal place.
Time frame: At the end of every 2 cycles until disease progression (Up to 31 months)
DCR Based on Investigator Review in Cohort A and B
DCR was defined as the percentage of participants experiencing a best overall response of SD, PR, or CR (per RECIST 1.1), based on IRC. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referencing the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of target lesion diameters from the smallest on study (including baseline), with an absolute increase of ≥ 5 mm, or the appearance of new lesions. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. Percentages were rounded off to the nearest single decimal place.
Time frame: At the end of every 2 cycles until disease progression (Up to 31 months)
CR+ Complete Response With Incomplete Hematological Recovery (CRi) Rate in Cohort C
CR+CRi rate was defined as the percentage of participants who achieved a CR or CRi.
Time frame: Up to 31 months
Duration of CR in Cohort C
Duration of CR was defined as the time from the first documentation of CR to the first documentation of recurrence or death due to any cause, whichever occurs first.
Time frame: Up to 31 months
Duration of CR+CRi in Cohort C
Duration of CR+CRi was defined as the time from the first documentation of CR or CRi to the first documentation of disease relapse or death due to any cause, whichever occurs first.
Time frame: Up to 31 months
Complete Cytogenetic Response (CCyR) Rate in Cohort C
CCyR rate was defined as the percentage of participants who achieved a CCyR.
Time frame: Up to 31 months
Partial Cytogenetic Response (PCyR) Rate in Cohort C
PCyR rate was defined as the percentage of participants who achieved a PCyR.
Time frame: Up to 31 months
Relapse-free Survival (RFS) in Cohort C
RFS was defined as the time from first documentation of CR to the date of death (any cause) or disease relapse or death due to any cause, whichever occurs first.
Time frame: Up to 31 months
Event-free Survival (EFS) in Cohort C
EFS was defined as the time from first dose of study therapy to treatment failure, disease relapse after CR, or participant death due to any cause, whichever occurs first.
Time frame: Up to 31 months
Number of Participants With Treatment Emergent Adverse Events (TEAEs) - Cohort A, B and C
An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant and does not necessarily have a causal relationship with the study drug. A treatment-emergent AE (TEAE) is defined as an AE that is starting or worsening at the time of or after the first dose of study drug administration and within 30 days after the last dose of study drug, and does not necessarily have a causal relationship to the use of the study drug.
Time frame: From the first dose of study drug up to 30 days after the last dose (Up to 31 months)
Participants took part in the study from 05 August 2020 to 11 November 2024.
| Milestone | Futibatinib (Cohort A) | Futibatinib (Cohort B) | Futibatinib (Cohort C) |
|---|---|---|---|
| Started | 87 | 28 | 0 |
| Completed | 0 | 0 | 0 |
| Not completed | 87 | 28 | 0 |
| Withdrew: Withdrawal of consent | 8 | 1 | 0 |
| Withdrew: Study terminated by sponsor | 25 | 3 | 0 |
| Withdrew: Death | 54 | 24 | 0 |
ORR was defined as the percentage of participants experiencing a best overall response of partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors, RECIST version 1.1), based on IRC of radiological images. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. ORR was calculated based on the best overall response recorded from the start of treatment until progressive disease or start of subsequent new anticancer treatment. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Futibatinib (Cohort A) | Futibatinib (Cohort B) |
|---|---|---|
| Objective Response Rate (ORR) Based on Independent Central Review (IRC) in Cohorts A and B | 6.9 (2.6 to 14.4) | 17.9 (6.1 to 36.9) |
CR rate was defined as the percentage of participants who achieved a CR (per response criteria for myeloid or lymphoid neoplasm) based on investigator assessment of imaging, peripheral blood, and bone marrow. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm.
No measurements were reported for this outcome.
ORR was defined as the percentage of participants experiencing a best overall response of PR or CR (per RECIST 1.1), based on investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. ORR was calculated based on the best overall response recorded from the start of treatment until progressive disease or start of subsequent new anticancer treatment. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Futibatinib (Cohort A) | Futibatinib (Cohort B) |
|---|---|---|
| ORR Based on Investigator Assessment in Cohorts A and B | 9.2 (4.1 to 17.3) | 10.7 (2.3 to 28.2) |
DOR was defined as the time from the first documentation of response (CR or PR in based on IRC) to the first documentation of objective tumor progression or death due to any cause, whichever occurs first. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. DOR was estimated using the Kaplan-Meier method.
| months | Futibatinib (Cohort A) | Futibatinib (Cohort B) | Futibatinib (Cohort C) |
|---|---|---|---|
| Duration of Response (DOR) Based on IRC in Cohorts A, B and C | 5.6 (3.5 to NA) | 3.9 (2.1 to NA) | — |
DOR was defined as the time from the first documentation of response (CR or PR in based on Investigator Assessment) to the first documentation of objective tumor progression or death due to any cause, whichever occurs first. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. DOR was estimated using the Kaplan-Meier method.
| months | Futibatinib (Cohort A) | Futibatinib (Cohort B) | Futibatinib (Cohort C) |
|---|---|---|---|
| DOR Based on Investigator Assessment in Cohorts A, B and C | 5.6 (3.0 to NA) | 5.6 (2.0 to NA) | — |
PFS was defined as the time from first dose of the study therapy to the date of death (any cause) or disease progression (based on IRC), whichever occurs first. The PFS was analyzed using a Kaplan-Meier method, with PFS time being censored on the date of the last disease assessment. The 95% CI for median PFS was provided using the Kaplan-Meier procedure.
| months | Futibatinib (Cohort A) | Futibatinib (Cohort B) | Futibatinib (Cohort C) |
|---|---|---|---|
| Progression- Free Survival (PFS) Based on IRC in Cohorts A, B and C | 1.9 (1.8 to 3.5) | 2.9 (1.8 to 3.7) | — |
PFS was defined as the time from first dose of the study therapy to the date of death (any cause) or disease progression (based on Investigator Review), whichever occurs first. The PFS was analyzed using a Kaplan-Meier method, with PFS time being censored on the date of the last disease assessment. The 95% CI for median PFS was provided using the Kaplan-Meier procedure.
| months | Futibatinib (Cohort A) | Futibatinib (Cohort B) | Futibatinib (Cohort C) |
|---|---|---|---|
| PFS Based on Investigator Review in Cohorts A, B and C | 3.3 (1.9 to 3.8) | 3.3 (2.1 to 3.7) | — |
OS was defined as the time from the date of first dose to the death date. Participants without a documented death date were censored on the last date they were known to be alive. The OS was presented using a Kaplan-Meier estimate. The 95% CI for median OS was provided using the Kaplan-Meier procedure.
| months | Futibatinib (Cohort A) | Futibatinib (Cohort B) | Futibatinib (Cohort C) |
|---|---|---|---|
| Overall Survival (OS) in Cohorts A, B and C | 11.1 (7.3 to 15.6) | 5.9 (3.9 to 8.9) | — |
DCR was defined as the percentage of participants experiencing a best overall response of stable disease (SD), PR, or CR (per RECIST 1.1), based on IRC. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), referencing the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of target lesion diameters from the smallest on study (including baseline), with an absolute increase of ≥ 5 mm, or the appearance of new lesions. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Futibatinib (Cohort A) | Futibatinib (Cohort B) |
|---|---|---|
| Disease Control Rate (DCR) Based on IRC in Cohort A and B | 37.9 (27.7 to 49.0) | 50.0 (30.6 to 69.4) |
DCR was defined as the percentage of participants experiencing a best overall response of SD, PR, or CR (per RECIST 1.1), based on IRC. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referencing the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of target lesion diameters from the smallest on study (including baseline), with an absolute increase of ≥ 5 mm, or the appearance of new lesions. CR was defined as disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters. Percentages were rounded off to the nearest single decimal place.
| percentage of participants | Futibatinib (Cohort A) | Futibatinib (Cohort B) |
|---|---|---|
| DCR Based on Investigator Review in Cohort A and B | 52.9 (41.9 to 63.7) | 64.3 (44.1 to 81.4) |
CR+CRi rate was defined as the percentage of participants who achieved a CR or CRi.
No measurements were reported for this outcome.
Duration of CR was defined as the time from the first documentation of CR to the first documentation of recurrence or death due to any cause, whichever occurs first.
No measurements were reported for this outcome.
Duration of CR+CRi was defined as the time from the first documentation of CR or CRi to the first documentation of disease relapse or death due to any cause, whichever occurs first.
No measurements were reported for this outcome.
CCyR rate was defined as the percentage of participants who achieved a CCyR.
No measurements were reported for this outcome.
PCyR rate was defined as the percentage of participants who achieved a PCyR.
No measurements were reported for this outcome.
RFS was defined as the time from first documentation of CR to the date of death (any cause) or disease relapse or death due to any cause, whichever occurs first.
No measurements were reported for this outcome.
EFS was defined as the time from first dose of study therapy to treatment failure, disease relapse after CR, or participant death due to any cause, whichever occurs first.
No measurements were reported for this outcome.
An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant and does not necessarily have a causal relationship with the study drug. A treatment-emergent AE (TEAE) is defined as an AE that is starting or worsening at the time of or after the first dose of study drug administration and within 30 days after the last dose of study drug, and does not necessarily have a causal relationship to the use of the study drug.
| Participants | Futibatinib (Cohort A) | Futibatinib (Cohort B) | Futibatinib (Cohort C) |
|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) - Cohort A, B and C | 87 | 27 | — |
Collected over From the first dose of study drug up to 30 days after the last dose (Up to 31 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Futibatinib (Cohort A) | 54/87 (62.1%) | 23/87 (26.4%) | 86/87 (98.9%) |
| Futibatinib (Cohort B) | 24/28 (85.7%) | 6/28 (21.4%) | 27/28 (96.4%) |
| Event | Futibatinib (Cohort A) | Futibatinib (Cohort B) |
|---|---|---|
| VomitingGastrointestinal disorders | 0/87 | 2/28 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/87 | 0/28 |
| General physical health deteriorationGeneral disorders | 2/87 | 1/28 |
| PneumoniaInfections and infestations | 2/87 | 1/28 |
| Decreased appetiteMetabolism and nutrition disorders | 2/87 | 1/28 |
| Abdominal painGastrointestinal disorders | 0/87 | 1/28 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/87 | 1/28 |
| HaemobiliaHepatobiliary disorders | 0/87 | 1/28 |
| Spinal compression fractureInjury, poisoning and procedural complications | 0/87 | 1/28 |
| Malignant pleural effusionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/87 | 1/28 |
| Event | Futibatinib (Cohort A) | Futibatinib (Cohort B) |
|---|---|---|
| HyperphosphataemiaMetabolism and nutrition disorders | 70/87 | 25/28 |
| DiarrhoeaGastrointestinal disorders | 36/87 | 6/28 |
| Decreased appetiteMetabolism and nutrition disorders | 18/87 | 10/28 |
| ConstipationGastrointestinal disorders | 28/87 | 3/28 |
| Aspartate aminotransferase increasedInvestigations | 15/87 | 7/28 |
| Dry mouthGastrointestinal disorders | 20/87 | 1/28 |
| Alanine aminotransferase increasedInvestigations | 19/87 | 6/28 |
| NauseaGastrointestinal disorders | 8/87 | 6/28 |
| AnaemiaBlood and lymphatic system disorders | 16/87 | 3/28 |
| FatigueGeneral disorders | 15/87 | 4/28 |
All treated population included all participants who received at least 1 dose of study drug. No participant was enrolled in Cohort C, hence no data was collected.
| Age, Continuous(years) | Futibatinib (Cohort A) | Futibatinib (Cohort B) | Total |
|---|---|---|---|
| Mean | 60.0 ± 12.47 | 55.6 ± 13.77 | 58.9 ± 12.87 |
| Sex: Female, Male(Participants) | Futibatinib (Cohort A) | Futibatinib (Cohort B) | Total |
|---|---|---|---|
| Female | 47 | 16 | 63 |
| Male | 40 | 12 | 52 |
| Race/Ethnicity, Customized(Participants) | Futibatinib (Cohort A) | Futibatinib (Cohort B) | Total |
|---|---|---|---|
| Race — Caucasian/White | 29 | 3 | 32 |
| Race — Black or African American | 1 | 0 | 1 |
| Race — Asian | 36 | 24 | 60 |
| Race — Other | 1 | 0 | 1 |
| Race — Unknown | 20 | 1 | 21 |
| Race/Ethnicity, Customized(Participants) | Futibatinib (Cohort A) | Futibatinib (Cohort B) | Total |
|---|---|---|---|
| Ethnicity — Hispanic or Latino | 3 | 1 | 4 |
| Ethnicity — Not Hispanic or Latino | 62 | 26 | 88 |
| Ethnicity — Unknown | 22 | 1 | 23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2020 to primary completion in Nov 2024, 51 months.
Results were first posted in Oct 2025, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Futibatinib